ERα基因单核苷酸多态性与乳腺癌应用芳香化酶抑制剂引发骨丢失的相关性研究

doi:10.11904/j.issn.1002-3070.2018.01.003

实用肿瘤学杂志 ›› 2018, Vol. 32 ›› Issue (1): 14-18.doi: 10.11904/j.issn.1002-3070.2018.01.003

ERα基因单核苷酸多态性与乳腺癌应用芳香化酶抑制剂引发骨丢失的相关性研究

殷玉莲¹, 张卫红², 周悦¹, 叶媚娜¹, 陈红风¹

1.上海中医药大学附属龙华医院中医乳腺科(上海 200032);
2.上海市宝山区中西医结合医院乳腺外科

收稿日期:2017-10-23 出版日期:2018-02-20 发布日期:2018-03-07
通讯作者: 陈红风,E-mail:chhfluk@126.com
作者简介:殷玉莲,女,(1990-),硕士,住院医师,从事乳腺疾病中西医结合治疗的研究。
基金资助:
上海市海派中医流派传承研究基地建设项目(ZY3-CCCX-1-1004);上海市卫生和计划生育委员会科研项目(201540036)

Correlation between single nucleotide polymorphisms of ERα gene and bone loss associated with aromatase inhibitors in postmenopausal women with breast cancer

YIN Yulian¹, ZHANG Weihong², ZHOU Yue¹, YE Meina¹, CHEN Hongfeng¹

1.Department of Breast Disease,Longhua Hospital Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China;
2.Department of Breast Surgery,Baoshan Branch of Shuguang Hospital,Affiliated to Shanghai University of TCM

Received:2017-10-23 Online:2018-02-20 Published:2018-03-07

摘要/Abstract

摘要： 目的探索乳腺癌术后应用芳香化酶抑制剂(AIs)引起的骨代谢异常与ERα基因rs9340799、rs2234693位点单核苷酸多态性(SNPs)之间的相关性。方法将2015年10月—2017年4月期间在我院门诊及住院治疗的116名乳腺癌术后接受AIs治疗(≤2年)的患者行ERα基因rs9340799、rs2234693位点测序并比较各基因亚型的腰椎、股骨的骨密度(BMD)值以及T值之间的关系。结果 ERα基因rs9340799位点3个亚型(A/A、A/G、G/G)患者的腰椎BMD值比较具有统计学差异(P＜0.05)。A/A、A/G基因型患者的腰椎BMD值均高于G/G基因型患者(P＜0.05);ERα基因rs2234693位点的3个基因亚型(T/T、C/T、C/C)患者的腰椎BMD值比较具有统计学差异(P＜0.05),T/T、C/T基因型患者的腰椎BMD均高于C/C基因型患者(P＜0.05)。但两位点各基因亚型患者的股骨BMD值、腰椎T值、股骨T值组间比较均无统计学差异(P＞0.05)。结论芳香化酶抑制剂相关骨丢失(AIBL)的发生可能与ERα基因表型相关。ERα基因rs9340799与rs2234693位点中,C、G等位基因可能是发生AIBL的易感型基因。

关键词: 乳腺癌, 芳香化酶抑制剂, 骨代谢异常, ERα基因, 单核苷酸多态性

Abstract: Objective The aim of this study was to explore the correlation between postoperative aromatase inhibitor(AIs)- based bone metabolism and ERα gene rs9340799,rs2234693 single nucleotide polymorphisms(SNPs)in breast cancer. Methods One hundred and sixty-six breast cancer patients who underwent AIs treatment(≤2 years)were enrolled and hospitalized in our hospital from October 2015 to April 2017.The ERα gene rs9340799 and rs2234693 sites were sequenced and compared subtype of lumbar spine and femur,bone mineral density BMD value and the relationship between BMD value and T value. Results The BMD of lumbar spine in patients with ERα gene rs9340799 was significantly different when compared to those of A/A,A/G and G/G(P＜0.01).The BMD of lumbar spine in patients with A/A and A/G genotypes were significantly higher than those in G/G genotypes(P＜0.05).The BMD of lumbar spine in patients with ERα gene rs2234693 was significantly different when compared to those of T/T,T/C and C/C(P＜0.01).The BMD of lumbar spine in patients with T/T and C/T genotypes were significantly higher than those in C/C genotypes(P＜0.05).However,there was no difference in femoral BMD,lumbar spine,and femur T between the 2 subtypes of patients with genotypes(P＞0.05). Conclusion Aromatase inhibitor-related bone loss(AIBL)may be related to ERα gene phenotype.In ERα gene rs9340799 and rs2234693 loci,C and G alleles may be susceptible genes for aromatase inhibitor-related bone loss(AIBL).

Key words: Breast cancer, Aromatase inhibitors, Abnormal bone metabolism, ER α genes, Single nucleotide polymorphisms

中图分类号:

R737.9
R336

殷玉莲, 张卫红, 周悦, 叶媚娜, 陈红风. ERα基因单核苷酸多态性与乳腺癌应用芳香化酶抑制剂引发骨丢失的相关性研究[J]. 实用肿瘤学杂志, 2018, 32(1): 14-18.

YIN Yulian, ZHANG Weihong, ZHOU Yue, YE Meina, CHEN Hongfeng. Correlation between single nucleotide polymorphisms of ERα gene and bone loss associated with aromatase inhibitors in postmenopausal women with breast cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 14-18.

参考文献

1 陈万青,郑荣寿.中国女性乳腺癌发病死亡和生存状况[J].中国肿瘤临床,2015,42(13):668-674.
2 中国乳腺癌内分泌治疗专家共识专家组.中国乳腺癌内分泌治疗专家共识[J].中国癌症杂志,2015,25(9):755-759.
3 Luo LM,Xia WB,Nie M,et al.Association of ESR1 and C6 or f97 gene polymorphism with osteoporosis in postmenopausal women[J].Mol Biol Rep,2014,41:3235-3243.
4 付映旭,胥伯勇,阿斯哈尔江·买买提依明,等.雌激素受体α基因PvuⅡ位点多态性与女性膝骨关节炎相关性的Meta分析[J].中国矫形外科杂志,2015,23(13):1183-1187.
5 Erdogan MO,Yildiz H,Artan S,et al.Association of estrogen receptor alpha and collagen type I alpha 1 gene polymorphisms with bone mineral density in postmenopausal women[J].Osteoporos Int,2011,22(4):1219-1225.
6 Iwasaki M,Hamada GS,Nishimoto IN,et al.Isoflavone,polymorphisms in estrogen receptor genes and breast cancer risk in case-control studies in Japanese,Japanese Brazilians and non-Japanese Brazilians[J].Cancer Sci,2009,100(5):927-933.
7 周悦,陈红风,叶媚娜,等.ERα基因SNPs与乳腺癌芳香化酶抑制剂治疗所致骨代谢异常的关系[J].中国骨质疏松杂志,2016,22(8):998-1003.
8 陈荣滋,陈昆,刘爱刚,等.妇女围绝经期雌激素水平与骨质疏松发生的临床分析[J].中国妇幼健康研究,2016,27(7):811-812.
9 Cuzick J,Sestak I,Baum M,et al.Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer:10-year analysis of the ATAC trial[J].Lancet Oncol,2010,11(12):1135-1141.
10 Colleoni M,Giobbie-Hurder A,Regan MM,et al.Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study[J].J Clin Oncol,2011,29(9):1117-1124.
11 Chlebowski RT,Budoff MJ.Changing adjuvant breast-cancer therapy with a signal for prevention[J].N Engl J Med,2016,375(3):274-275.
12 Huang B,Omoto Y,Iwase H,et al.Differential expression of estrogen receptor alpha,beta1,and beta2 in lobular and ductal breast cancer[J].Proc Natl Acad Sci,2014,111(5):1933-1938.
13 曹兰青,李卉,刘莉,等.四川省女性ERα基因多态性与乳腺癌风险关系的病例对照研究[J].肿瘤预防与治疗,2014,27(4):171-175.
14 邓黎黎,陆云飞.雌激素α受体基因XbaI和PvuII多态性与乳腺癌关系的研究[J].中国癌症防治杂志,2011,3(1):19-22.
15 汪曾荣.老年女性髋部骨质疏松发病中雌激素受体基因多态性分布的年龄差异[J].中国组织工程研究,2015,19(7):991-995.
16 王伟,曹靖,李亚辉.雌激素α受体基因多态性与绝经后女性骨质疏松症相关性研究[J].河南医学高等专科学校学报,2017,29(1):11-15.
17 Dai X,Wang C,Dai J,et al.Association of single nucleotide polymorphisms in estrogen receptor alpha gene with susceptibility to knee osteoarthritis:a case-control study in a Chinese Han population[J].Biomed Res Int,2014,2014:151457.
18 宋传贵,胡震,袁文涛,等.ER基因多态性与无BRCA1/2基因突变的有遗传倾向的乳腺癌的关系[J].中华普通外科杂志,2006,21(9):637-640.

[1]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[2]	李烁,张楠楠,李亮亮,龙志平,尹慧慧,赵亚双,王帆. 外周血白细胞PDE4C基因甲基化及环境因素交互作用与乳腺癌发病的关系[J]. 实用肿瘤学杂志, 2019, 33(3): 233-238.
[3]	李嘉琪,栾瑾微,张,玉,李香兰. 763例三阴性乳腺癌临床病理特征及复发、转移影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(3): 244-249.
[4]	刘佳音,燕飞虎,张艳桥. 凋亡基因Caspase3和Caspase7单核苷酸多态性与胃癌遗传易感性研究[J]. 实用肿瘤学杂志, 2019, 33(3): 250-255.
[5]	陈艳波, 孔德嘉, 张金锋, 马志刚. 乳腺癌患者CYP2D6基因多态性与他莫昔芬代谢相关性研究[J]. 实用肿瘤学杂志, 2019, 33(2): 110-114.
[6]	孙江宏, 郝明珠, 姜丹, 国飞, 李晓梅. 乳腺炎、良性增生及乳腺癌FFDM鉴别诊断思路[J]. 实用肿瘤学杂志, 2019, 33(2): 139-141.
[7]	马志杰, 王帆, 赵亚双. 乳腺癌化疗患者生存质量及影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(2): 149-154.
[8]	马质莹, 尚乃舰, 蔡妙田, 沈阳, 姜智允. 孕激素及雌激素受体阳性乳腺癌HER-2受体与钼靶影像学特征及临床病理学特征的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(1): 47-51.
[9]	胡智慧综述, 张静审校. SNP对放射性肺损伤预测作用的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 87-91.
[10]	何煦, 叶尚勉, 董丹丹, 李科. HLA-G在乳腺癌中的表达及意义[J]. 实用肿瘤学杂志, 2018, 32(5): 410-414.
[11]	林荣杰, 尹航, 周云峰. ON123300对ER阳性人乳腺癌MCF-7细胞的影响及机制研究[J]. 实用肿瘤学杂志, 2018, 32(3): 193-197.
[12]	李林(综述), 李志高(审校). 二甲双胍与不同分子亚型乳腺癌的关系[J]. 实用肿瘤学杂志, 2018, 32(3): 267-270.
[13]	郑伟, 许守平, 庞达. 长链非编码RNA Linc00152在泛癌中表达、预后及功能研究[J]. 实用肿瘤学杂志, 2018, 32(1): 7-13.
[14]	黎玉娇, 尚乃舰. 影像学评估乳腺癌新辅助化疗反应的研究进展[J]. 实用肿瘤学杂志, 2018, 32(1): 63-67.
[15]	陈琢, 孔艺然. 沉默UHRF1对乳腺癌细胞增殖和转移的影响[J]. 实用肿瘤学杂志, 2017, 31(6): 512-518.

ERα基因单核苷酸多态性与乳腺癌应用芳香化酶抑制剂引发骨丢失的相关性研究

Correlation between single nucleotide polymorphisms of ERα gene and bone loss associated with aromatase inhibitors in postmenopausal women with breast cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价